San Francisco startup Framework Therapeutics is also working on an oral, once-day-to-day GLP-1 drug referred to as GSBR-1290—the drug surpassed Wall Avenue’s expectations in June any time a mid-phase study showed regular weight loss of all over six% and it ideas to start One more mid